Reuters reported that Jubilant Life Sciences Ltd. reached a non-exclusive licensing agreement for Gilead Sciences Inc.'s Covid-19 treatment remdesivir. "Jubliant Life Sciences in Non-Exclusive Agreement for Gilead Covid-19 Drug --Reuters" at 2:42 p.m. ET misspelled the company's name as Jubliant in the headline and second paragraph.

(END) Dow Jones Newswires

May 12, 2020 15:13 ET (19:13 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Gilead Sciences Charts.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Gilead Sciences Charts.